Animal health, which for decades was little more than a side business for big pharma companies, has emerged as a beacon of growth and an important profit driver in the industry. The rise of animal health as a growth engine has set off a flurry of deal making, attracted an influx of capital and created an increasingly dynamic marketplace for pet and livestock pharmaceuticals.
Translational medicine, which bridges the science of the emerging preclinical portfolio and the early development space where molecules are studied in humans for the first time, is an important if not essential element of successful pharmaceutical development.
Drug repurposing is ultimately an expedition into uncharted territory. Phenotypic screening, which involves testing agents of interest directly in relevant animal models across a number of therapeutic areas, has potential to discover new biology and could make the process of drug development more efficient by shortening development timelines.
Rep. Rosa DeLauro's recent letter to the FDA criticizing expedited approval pathways designed to accelerate the commercialization of innovative treatments does not capture the role of FDA's expedited approval programs in speeding therapies to patients suffering from unmet medical needs and faced with few or no medical alternatives.
By David Grainger Clinical trial results are seldom reported in a form that is accessible to the public. To many people that is unacceptable for several reasons: it allows drug companies to...
By David Grainger Late-stage attrition kills returns on pharma R&D investment. One way to reduce attrition is to take less risk-- incremental innovation reduces the risk of failing in development...
By Michelle Rohrer, Vice President, U.S. Regulatory Affairs, Genentech In August I had the pleasure of participating in Fierce's "Understanding Major Regulatory Change" webinar. This...
While just about any new treatment option for migraine would be welcomed by patients and physicians, there is clearly a need to pursue new disease targets in order to develop improved therapeutics for this debilitating disorder.
Spending on platforms prevents big pharma from properly addressing the cost problem in drug discovery and development and unless it is addressed such platforms may ultimately prove their nemesis rather than their saviour.
Disraeli supposedly said "The only two certainties in life are death and taxes," but if a team of Croatian scientists, led by Professor Miroslav Radman, is correct, death need be no certainty.